Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2018

View Archived Issues

Rhythm acquires rights to Takeda GOAT inhibitor for Prader-Willi syndrome

Relationship between PACE4 expression and prognosis differs in colorectal cancer

PRAME found highly expressed in salivary gland cancer

FDA grants BLA priority review for moxetumomab pasudotox in hairy cell leukemia

FDA grants fast track designation for TAR-200 in muscle invasive bladder cancer

Retrophin initiates pivotal phase III DUPLEX study of sparsentan

Novartis patents new TLR7/8/9 antagonists

MedImmune divulges novel anti-VEGF-A antibodies for cancer

Novel secretomes disclosed by researchers from Korea

Eli Lilly discovers HAVcr-2-targeting antibodies

Phase I trial of KA-34 is currently recruiting participants

FDA grants orphan drug designation for BPN-14770 as treatment of fragile X syndrome

PRDM15-targeting ASOs presented by A*STAR

Topline results from phase II study of fostamatinib in IgA nephropathy

European Commission grants orphan drug designation to Altemia for sickle cell disease

Patient recruitment ongoing in phase I/II trial of ST-400

EMA validates MAA for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer

GenSight reports topline results from REVERSE trial of GS-010 in LHON

Personal Genome Diagnostics, Five Prime Therapeutics to develop bemarituzumab companion diagnostic

SpinalCyte reports data from phase I/II trial of CybroCell

ThromboGenics reports phase I/II topline data on THR-317 for DME

Eisai submits sNDA for pediatric use of Fycompa

Pfizer and Allogene enter asset contribution agreement for Pfizer's CAR T portfolio

SOX-9 unveiled as potential prognostic marker in lymphoma

Sellas reports interim phase IIb data on Herceptin + NeuVax in breast cancer

Nkx-6.1 identified as diagnostic marker of lung and pancreatic NETs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...